Tyme Technologies, LLC

[Not Yet Scheduled]
TYME is an emerging biotech company that won "Best Public Company Presentation" at BioNJ 2019 Biopartnering Conference, and was featured by NJEDA at BIO2019. TYME is developing cancer therapeutics that are intended to be broadly effective across tumor types and have low toxicity profiles. Unlike targeted therapies that attempt to regulate specific mutations within cancer, our therapeutic approach is designed to take advantage of a cancer cell’s innate metabolic weaknesses to compromise its defenses, leading to cell death through oxidative stress and exposure to the body’s natural immune system.

TYME has multiple cancer metabolism-based assets and formulations for SM-88 in the pipeline, including injectable, intranasal, and transdermal that are expected to advance into the clinical setting. TYME has an expanding patent portfolio covering compositions, methods, manufacturing and use of its pipeline to 2032, and beyond. TYME has 162 patent applications granted and/or pending worldwide.
Ticker:
TYME
Exchange:
NASDAQ
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
New York
Company HQ Country:
United States
Year Founded:
2012
Main Therapeutic Focus:
Lead Product in Development:
SM-88 (racemetyrosine)
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
three cancer metabolism-based compounds one which has confirmed clinical responses across 15 tumors
Speaker
photo
Chief Operating Officer
Tyme Technologies, LLC